Related Experiment Video
Updated: Jun 22, 2026
04:20
Knockdown of FAM83A to Verify Its Role in Cervical Cancer Cell Growth and Cisplatin Sensitivity
Published on: February 9, 2024
14-3-3sigma-dependent resistance to cisplatin
Zhiyong Han1, Konstantinos Dimas, Xuefei Tian
1Department of Preclinical Sciences, New York College of Podiatric Medicine, New York, NY 10035, U.S.A. zhan@nycpm.edu
Anticancer Research
|June 17, 2009
Summary
Cisplatin resistance in cancer cells can be overcome by targeting the 14-3-3sigma protein, which inhibits p53 activation and prevents cancer cell death. This finding offers new strategies for improving chemotherapy effectiveness.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Cisplatin resistance in cancer cells is a significant obstacle to successful chemotherapy.
- Understanding the molecular mechanisms of cisplatin resistance is crucial for developing effective cancer treatments.
Purpose of the Study:
- To investigate the role of 14-3-3sigma in cisplatin resistance in human colon cancer cells.
- To elucidate the molecular pathways involving p53, p21, and senescence in response to cisplatin treatment.
Main Methods:
- Utilized clonogenicity assays to determine cisplatin sensitivity in HCT116 cells and isogenic knockout sub-lines.
- Assessed p53 activation, p21 expression, cell cycle arrest, and senescence following cisplatin treatment.
Main Results:
- 14-3-3sigma-knockout cells exhibited significantly higher sensitivity to cisplatin compared to parental cells.
- Low-dose cisplatin treatment induced p53 activation, p21 expression, and senescence in 14-3-3sigma-knockout cells, but not in parental cells.
Conclusions:
- A 14-3-3sigma-dependent mechanism suppresses p53 activation in response to low-dose cisplatin.
- This suppression blocks p21-dependent senescence, leading to cisplatin resistance in parental cancer cells.
- Targeting 14-3-3sigma may represent a viable strategy to enhance the efficacy of cisplatin chemotherapy.
Related Concept Videos
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:18Other Unique Bacteria
Magnetic bacteria exhibit a directed movement called magnetotaxis, driven by structures called magnetosomes. These magnetosomes consist of chains of magnetic particles made of either magnetite (Fe₃O₄) or greigite (Fe₃S₄) and are organized in a linear conformation by a protein scaffold within invaginations of the cell membrane. The bacteria align along the north–south magnetic field lines, much like a compass needle. They are typically microaerophilic or anaerobic and are commonly found near the...
01:25Clinical Significance of Antibiotic Resistance
Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within the One...